MASH / MASLD

Positive topline results show the trial met its primary endpoint for MASH resolution and fibrosis improvement, with significant weight loss effects without plateauing.

A recent cross-sectional analysis has estimated the size of the American population with both MASLD and T2DM eligible for treatment.

More frequently adding salt to food was associated with heightened risks of MASLD, cirrhosis, and hepatocellular carcinoma.

Patients with alcohol-associated liver disease and MetALD had greater risks of adverse liver outcomes and all-cause mortality than those with MASLD.

Findings highlight an increased risk of MASLD, heart failure, type 2 diabetes, and other cardiometabolic diseases following cycles of weight loss and regain.

In the second part of a 2-part episode, hosts Kimberly Brown and Nancy Reau break down 3 more notable abstracts from the 2025 EASL Congress.

The month in review spotlights hepatic podcast episodes from HCPLive, new clinical trial data, and coverage from DDW.

Hosts discuss a consensus repot from the ADA focused on screening and early interview of MASLD in people with diabetes.

Hosts Kimberly Brown and Nancy Reau break down 4 of the top abstracts presented at the 2025 European Association for the Study of the Liver (EASL) Congress.

Gyre Therapeutics plans to file an NDA in China based on the phase 3 CHB data and, pending IND clearance, is looking to initiate a phase 2 MASH fibrosis trial in the US.

Use of efruxifermin did not result in a significant reduction in fibrosis without worsening of MASH at week 36 compared with placebo in the phase 2b SYMMETRY trial.

Mazen Noureddin, MD, MHSc, reviews findings from a phase 2 study of efimosfermin alfa (BOS-580) for F2/F3 fibrosis due to MASH.

FibroX showed superior performance, interpretability, and potential cost savings relative to FIB-4, improving risk stratification and management in MASLD.

The month in review spotlights hepatic FDA and pipeline news as well as new research on alcohol and obesity's impact on liver health and PBC.

In this episode, hosts explore the promise of semaglutide 2.4 mg in improving liver outcomes for MASH in the Phase 3 ESSENCE trial.

New Phase 3 trial results reveal semaglutide's effectiveness in treating metabolic dysfunction-associated steatohepatitis, offering hope for millions.

Findings suggest the benefit of MASLD-focused anti-inflammatory interventions for promoting brain health and preventing accelerated brain aging.

Findings suggest greater physical activity volume and intensity are linked to a reduced risk of all-cause and cardiovascular disease mortality in MASLD.

Findings suggest frequent consumption of non-skimmed milk may heighten the risk of developing MAFLD.

The new global guideline consensus streamlines and simplifies existing MASLD recommendations from current guidelines and guidance documents.

Our Q1 recap for hepatology spotlights regulatory updates, clinical trial data, 2 new guidance documents, and the anniversary of a historic FDA approval.

Bariatric surgery was associated with improved overall survival at an acceptable health care cost within a 10-year horizon.

The month in review spotlights coverage of the anniversary of resmetirom’s FDA approval and research in autoimmune hepatitis, HBV vaccination, and MASLD.

Mantzoros explains the need for multidisciplinary MASLD care and how to balance lifestyle modifications with emerging medications.

Mantzoros explains factors contributing to the growing burden of MASLD and the need for collaboration between hepatology, primary care, and endocrinology.